Final overall survival (OS) of surufatinib plus PD-1/PD-L1 antibodies as maintenance therapy following first line (1L) platinum-based chemotherapy (Chemo) plus PD-1/PD-L1 antibodies in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)

Category Primary study
ConferenceEuropean Lung Cancer Congress (ELCC) 2025
Year 2025
This article has no abstract
Epistemonikos ID: 2c4abb70e2fc58fb6a42b1946be036869379c72b
First added on: Jan 22, 2026